Page last updated: 2024-09-03

clofarabine and Body Weight

clofarabine has been researched along with Body Weight in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Liu, XY; Luan, JJ; Song, JG; Wang, WS; Wang, YQ; Zhang, W; Zhang, YS; Zuo, J	1
Huang, J; Jacobson, P; Long-Boyle, J; Orchard, P; Rydholm, N; Smith, A; Tolar, J	1
Bonate, PL; Cunningham, CC; Gaynon, P; Jeha, S; Kadota, R; Lam, GN; Razzouk, B; Rytting, M; Steinherz, P; Weitman, S	1

Trials

1 trial(s) available for clofarabine and Body Weight

Article	Year
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Adenine Nucleotides; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Biological Availability; Body Weight; Child; Child, Preschool; Clofarabine; Creatinine; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Young Adult	2011

Article

Year

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.

Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4

Topics: Adenine Nucleotides; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Biological Availability; Body Weight; Child; Child, Preschool; Clofarabine; Creatinine; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Young Adult

2011

Other Studies

2 other study(ies) available for clofarabine and Body Weight

Article	Year
Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics. The Kaohsiung journal of medical sciences, 2016, Volume: 32, Issue:5 Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Body Weight; Circadian Rhythm; Clofarabine; Dose-Response Relationship, Drug; Female; Male; Mice; Organ Specificity; Time Factors; Toxicity Tests, Acute	2016
Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. Journal of clinical pharmacology, 2011, Volume: 51, Issue:5 Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Area Under Curve; Body Surface Area; Body Weight; Brain Diseases, Metabolic, Inborn; Child; Child, Preschool; Clofarabine; Drug Monitoring; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infusions, Intravenous; Male; Metabolic Clearance Rate; Minnesota; Models, Biological; Transplantation Conditioning; Young Adult	2011

Article

Year

Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics.

The Kaohsiung journal of medical sciences, 2016, Volume: 32, Issue:5

Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Body Weight; Circadian Rhythm; Clofarabine; Dose-Response Relationship, Drug; Female; Male; Mice; Organ Specificity; Time Factors; Toxicity Tests, Acute

2016

Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation.

Journal of clinical pharmacology, 2011, Volume: 51, Issue:5

Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Area Under Curve; Body Surface Area; Body Weight; Brain Diseases, Metabolic, Inborn; Child; Child, Preschool; Clofarabine; Drug Monitoring; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infusions, Intravenous; Male; Metabolic Clearance Rate; Minnesota; Models, Biological; Transplantation Conditioning; Young Adult

2011